FDA chief Tukaram flags huge price gaps in medical devices, seeks Centre’s intervention
The report cited that an IV set purchased for ₹11.05 had a declared MRP of ₹325, while an infusion set purchased for ₹11 had an MRP of ₹201.
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
The has urged the and the to intervene and regulate the massive price margins on medical devices and consumables. Highlighting markups as high as 2,841% on basic items like IV sets, the FDA Commissioner identified a structural regulatory gap where many medical devices fall outside the price capping mechanism of the , leading to exploitation of vulnerable patients.
UPSC Perspectives
Governance
This issue highlights a critical gap in India's health governance and regulatory framework. The pricing of pharmaceuticals and medical devices is governed by the , which operates under the . The , an independent body under the , enforces these prices. However, the FDA's findings expose a regulatory loophole: while essential (scheduled) medicines are subject to strict price caps based on market-based pricing, many medical devices and consumables remain non-scheduled. This allows manufacturers and distributors to set exorbitant Maximum Retail Prices (MRPs) disconnected from the actual trade or procurement cost. The lack of transparency and information asymmetry—where patients cannot negotiate or choose alternatives during emergency care—violates the principles of fair market practices and consumer protection. UPSC questions often focus on the effectiveness of regulatory bodies; here, the challenge is expanding the NPPA's mandate to cover essential medical devices to ensure affordability and equity in healthcare.
Social
The exorbitant markups on medical consumables directly impact out-of-pocket expenditure (OOPE), a major concern in India's healthcare system. High OOPE pushes millions into poverty each year, contradicting the goals of universal health coverage. The FDA Commissioner rightly framed this as a core public health issue. Patients admitted to hospitals are a captive market; they cannot shop around for cheaper syringes or catheters. When a ₹11 IV set is billed at ₹325, it disproportionately affects the marginalized and middle class. This situation underscores the need for health equity, where access to life-saving treatment shouldn't lead to financial ruin. The aims to reduce OOPE and ensure affordable healthcare. The current pricing structure of medical devices undermines this policy objective. For Mains, this serves as a potent case study on how unregulated markets in healthcare can lead to the exploitation of vulnerable populations and the necessity for robust state intervention to protect public welfare.
Economic
The massive gap between the trade price and the MRP of medical devices illustrates market failure in the healthcare sector due to information asymmetry and inelastic demand. In a normal market, consumers use price and information to make choices, driving competition and lowering prices. However, in emergency medical care, the consumer (patient) is disconnected from the decision-making process (doctor/hospital) and lacks the expertise to evaluate alternatives. This allows manufacturers to artificially inflate the MRP to offer higher margins to distributors and hospitals, rather than reflecting the true cost of production plus a reasonable profit. This practice is economically inefficient and socially detrimental. Bringing more medical devices under the would involve trade margin rationalization (TMR), a tool the government has increasingly used to cap the margins across the supply chain, as seen recently with some medical devices. This approach balances the need to keep healthcare affordable while ensuring the industry remains viable for investment and innovation.